Pooled analysis of LUX‐Lung 2, LUX‐Lung 3, and LUX‐Lung 6 clinical trials suggested that afatinib is effective in NSCLC tumors with uncommon EGFR mutation [17]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.